Principal Investigator Jean X. Jiang (@JeanJiangLab) pioneered the modulation of hemichannel activation using targeting antibodies. Her team at @UTHealthSA discovered two targeting antibodies: one to open the hemichannels and another to block. While other teams have been able to block hemichannels, Dr. Jiang’s team was the first to activate and open the hemichannel. “The Welch Foundation grant helps us tremendously because Welch is willing to invest in projects that could be high risk but also have the potential for very high impact, projects that would not be funded by traditional grants. One of the ways we mediate this risk is by switching approaches. Welch is terrific because they allow us to have this kind of flexibility.” Read more about Dr. Jiang and her team’s work here: buff.ly/3QxjWtM